A Pilot Project for Clinical Pharmacy Services in a Clinic for Children With Medical Complexity

Insights

Clinical pharmacy services in a pediatric complex care clinic identified approximately one drug therapy problem per patient. Pharmacist involvement is crucial for managing medication needs and ensuring continuity of care.

Area of Science:

  • Pediatric healthcare
  • Clinical pharmacy
  • Complex care medicine

Background:

  • Children with medical complexity often have significant drug-related needs.
  • Managing polypharmacy in this population presents unique challenges.
  • The role of clinical pharmacists in specialized pediatric clinics is not fully characterized.

Purpose of the Study:

  • To evaluate the impact of clinical pharmacy services in a pediatric complex care clinic.
  • To identify and characterize the drug-related needs of these children.
  • To define and develop the pharmacist's role within the clinic setting.

Main Methods:

  • A prospective descriptive study was conducted over 11 weeks.
  • A clinical pharmacist actively participated in clinic visits.
  • Data collected included patient characteristics, workload, and drug therapy problems.

Main Results:

  • A pharmacist attended 46 visits with 43 patients, identifying 42 drug therapy problems (35 actual, 7 potential).
  • The average rate was approximately one drug therapy problem per patient.
  • Common issues included incorrect dosage, untreated conditions, potential drug interactions, and adverse effects.

Conclusions:

  • Children with medical complexity face a high risk of drug therapy problems.
  • Integrating a clinical pharmacist into the clinic is beneficial for identifying, preventing, and resolving medication issues.
  • Pharmacist presence supports continuity of care for this vulnerable patient group.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
353
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
356
Primary Healthcare Services01:30

Primary Healthcare Services

Primary care promotes wellness and prevents disease. This care includes health promotion, education, protection (such as immunizations), early disease screening, and environmental considerations. Settings providing this type of healthcare include physician offices, public health clinics, school nursing, and community health nursing.
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...
2.3K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K